🚀 This move enhances their capabilities in monoclonal antibody (mAb) development.
💡 The automated system allows scalable bioprocessing from early development to large-scale manufacturing.
💰 It aims to optimize processes and reduce production costs.
🌍 This integration promises increased efficiency, benefiting clients and patients worldwide.
Introduction:
Celonic Group, a contract development and manufacturing organization (CDMO) based in Switzerland, has announced the integration of Merck’s Breez™ micro-bioreactor platform into its process development operations. This strategic move is anticipated to enhance the company’s capabilities in the development and production of monoclonal antibodies (mAbs), providing a scalable and efficient bioprocessing solution.
- Celonic Group’s integration of Merck’s Breez™ micro-bioreactor platform aims to improve mAb development and manufacturing processes.
- The Breez system is a fully automated, continuous perfusion cell culture platform with a capacity of 2 mL.
- Incorporating this technology is expected to accelerate upstream process optimization while minimizing production costs and maximizing operational efficiency.
- Dr. Samanta Cimitan, CEO of Celonic, highlighted that this integration is a pivotal step towards innovative bioprocessing solutions that benefit clients and patients globally.
- This development reflects a broader trend in the biotechnology industry towards enhanced productivity and cost-effectiveness in biologics manufacturing.
Conclusion:
The integration of Merck’s Breez™ micro-bioreactor platform into Celonic’s operations signifies a significant advancement in bioprocessing capabilities, which may ultimately enhance the efficiency and cost-effectiveness of monoclonal antibody production. This initiative not only aims to bolster Celonic’s market position but also underscores the ongoing evolution of biotechnological innovations that can meet growing demands in the pharmaceutical industry.
